COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND KRILL OIL AND METHODS OF USE THEREOF
The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
1 . A composition comprising:
krill oil; and
a fatty acid component comprising ethyl eicosapentaenoate.
2 . The composition of claim 1 , wherein the fatty acid component comprises at least about 80%, by weight of all fatty acids (and/or derivatives thereof) present in the fatty acid component, ethyl eicosapentaenoate.
3 . The composition of claim 1 , wherein the krill oil is present in an amount less than, about equal to, or greater than an effective amount of krill oil when administered as a monotherapy.
4 . The composition of claim 1 , wherein the krill oil is comprises EPA and DHA.
5 . The composition of claim 1 , wherein the krill oil is suspended in the ethyl eicosapentaenoate.
6 . The composition of claim 1 , wherein the fatty acid component comprises at least about 95%, by weight of all fatty acids (and/or derivatives thereof) presenting the fatty acid component, ethyl eicosapentaenoate.
7 . The composition of claim 1 , wherein the fatty acid component comprises no more than about 20%, by weight of all fatty acids (and/or derivatives thereof) present in the fatty acid component, docosahexaenoate or ester thereof.
8 . The composition of claim 1 , wherein the fatty acid component comprises no more than about 1%, by weight of all fatty acids (and/or derivatives thereof) present, of any single fatty acid other than ethyl eicosapentaenoate.
9 . The composition of claim 1 , wherein the krill oil is present in an amount of about 5 mg to about 3000 mg.
10 . The composition of claim 1 , wherein the ethyl eicosapentaenoate is present in an amount of about 400 mg to about 5000 mg.
11 . The composition of claim 10 , wherein the ethyl eicosapentaenoate is present in an amount of about 400 mg to about 600 mg.
12 . The composition of claim 1 , wherein the krill oil is dispersed or suspended in the ethyl eicosapentaenoate.
13 . A method of treating or preventing a cardiovascular-related disease or disorder in a subject comprising administering to the subject a composition comprising krill oil and a fatty acid component comprising at least about 80%, by weight of all fatty acids (and/or derivatives thereof) present in the fatty acid component, ethyl eicosapentaenoate.
14 . The method of claim 13 , wherein the cardiovascular-related disease or disorder is hyperlipidemia or homozygous familial hypercholesterolemia (HoFH).
15 . The method of claim 13 , wherein the subject has a baseline fasting triglyceride level of about 200 mg/dl to about 499 mg/dl.
16 . The method of claim 15 , wherein the subject is on statin therapy.
17 . The method of claim 13 , wherein the subject has a baseline fasting triglyceride level of at least about 500 mg/dl.
18 . The method of claim 13 , wherein the subject is administered the composition for a period of time to effect a reduction in triglyceride levels of at least about 5%.
19 . The method of claim 13 , wherein the fatty acid component comprises at least about 90%, by weight of all fatty acids (and/or derivatives thereof) present in the fatty acid component, ethyl eicosapentaenoate.
20 . The method of claim 13 , wherein the composition comprising krill oil and the fatty acid component comprising ethyl eicosapentaenoate are present in a single dosage form.
21 . The method of claim 13 , wherein the krill oil is in a dosage form separate from the fatty acid component.
22 . A method of treating a cardiovascular-related disease or disorder in a subject on krill oil therapy, the method comprising administering to the subject a composition comprising a fatty acid component comprising at least about 80%, by weight of all fatty acids (and/or derivatives thereof) present in the fatty acid component, ethyl eicosapentaenoate.